Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
H. Thomson, N Harper et al. 2007 United Kingdom | 1 adult female with refractory asthma Intervention: endotracheal intubation and inhalational isofluorane using the AnaConDa™ Anaesthetic Conserving Device. | Case report (level 4) | Full recovery | Morbidity outcome not evaluated. Single case report. | |
L. Revich, S. Grinspon et al. 2001 Brazil | 1 adult patient with refractory asthma. Intervention: Treated on ICU for 7 hours with halothane 0.5% - 2% | Case report (level 4) | Mortality | Survival | Single patient analysis. The patient received continuous nebulized salbutamol (0.05mg/kg/h), intravenous hydrocortisone (400 mg/day), aminophylline (0.5 mg/kg/h) and AMV in the hypoventilation control mode. This patient also required treatment with dobutamine. Difficult to find single factor which accounted for recovery |
Intubation length | 24 hours | ||||
Total hospital stay | 3 days | ||||
Pulmonary function tests | Normal on discharge | ||||
N. Mori, H. Nagata et al. 1996 Japan | 2 patients included: Adult male admitted to ICU following surgery. Endotracheal intubation triggered asthma attack. Inhalation of sevofluorane was started 33 h after the onset of the asthmatic attack. With inhalation of l%-3% sevofluorane, peak airway pressure decreased promptly to 16-20 cm H,O at the same tidal volume. Weaning from the ventilator was started 5 h after the start of sevofluorane and discontinued after 30 h. Patient discharged from ITU on day 5. Adult male with refractory status asthmaticus was admitted to ICU. Administration of dexamethasone and adrenaline did not lead to improvement of symptoms, so inhalation of 2% sevofluorane was started under pressure controlled ventilation with a peak airway pressure of 30 cm H,O, a frequency of 15 breaths/min, and 50% oxygen by a Servo 900C. Because adequate ventilation was not achieved, the sevofluorane concentration was increased to 4%. Sevofluorane administration was gradually reduced on day 4 and discontinued on the following day. The patient was discharged from ICU on day 8. | Case series (level 4) | Renal function | U&E's and urine output remained stable. Patient survived. | End point only considered renal function. No follow up data for either patient. Overall length of stay in hospital unknown. Single outcome measure which does not consider overall effect of inhalational anaesthetic. Discharge pulmoary function tests not mentioned |
RG Johnston, TW Noseworthy et al. 1990 USA | 2 adult patients and 2 children admitted to hospital with refractory asthma (adult patients only used in paper review). Intervention | Case study (level 4) | Improvement of PCO2 value | PaCO2 35mmHG on admission, deteriorating to 65mmHg after twelve hours, PCO2 35mmHG after 16 hours of isoflurane therapy (patient 1). PaCO2 165mmHg improved to 35mmHG after 34 hours isoflurane (patient 2) | Length of hospital stay not recorded Discharge physiological parameters not recorded (PEFR, ABG) |
Full recovery | Laboratory tests reported as normal for both patients on discharge | ||||
F. Saulnier, A. Durocher et al. 1990 France | 12 patients (9 female, 3 male) admitted to a single unit ICU with status asthmaticus. Intervention: 1% halothane was administered to each patient for 30 minutes with physiological parameters recorded. | Prospective study (level 2) | Arterial blood gas | pH mean 7.21 increased to 7.25 post halothane. p < 0.001. PCO2 decreased from mean 82mmHg to 73 mmHg. p < 0.001. No significant change in PaO2 | Halothane commenced at different times for each patient Patients not followed up long-term. No report on longterm outcome following halothane use Length of intubation, ICU or hospital stay not recorded |
Peak inspiratory pressure | Mean 55cm H2O pre halothane. Mean 47cm H2O post halothane. p < 0.001. Significant drop in PIP | ||||
Mean pulmonary arterial pressure | 30mmHg prior to halothane, 25mmHg post halothane. p < 0.005 | ||||
Cardiac index (l/min/m2) | No significant change (3.9 - 3.6) | ||||
Pulse | 113 bpm significantly reduced to 106 bpm post halothane. p < 0.01 | ||||
T Schultz 2005 USA | 26 year old female with status asthmaticus Intervention: Sevoflurane administration until patient was stable for transfer to tertiary facility | Case study (level 4) | Mortality | Survival | Single patient case study report from nursing staff No record of post anaesthetic arterial blood gas values or physiological parameters. No record of additional medical therapy |
Length of intubation | 5 days | ||||
Total hospital stay | 7 days | ||||
G Mutlu, P Factor et al 2002 USA | 2 female patients with refractory asthma requiring ventilation on ICU Intervention: Patient 1: sevoflurane administered 6 hours after intubation and ventilation. Administered for 2 hours. Patient 2: isoflurane therapy administered at 5% and reduced to between 1-2% for 30 hours | Case series (level 4) | Arterial blood gas | No improvement (patient 1) with worsening hypercapnea (pCO2 120 mm Hg pre anaesthetic 202 mm Hg post anaesthetic). Improvement in ABG (patient 2). pH improved from 6.99 to 7.07. PCO2 reduced from 212 mm Hg to 120 mmHg | Sevoflurane therapy discontinued at early stage. No evidence that sevoflurane made asthma worse. No record of dicharge pulmoary function tests Both patients had complications from asthma, including subcutaneous emphysema, pneumomediastinum and bilateral pneumothoraces (patient 1). Pneumomediastinum (patient 2). |
Length of intubation | 5 days (patient 2) | ||||
Length of hospital stay | 11 days | ||||
Mortality | Both patients survived. | ||||
H. Arakawa, T Takizawa et al. 2002 Japan | Single patient case study 19 year old female admitted with acute exacerbation of asthma unresponsive to 16 hours of medical therapy. The patient was intubated and ventilated with isoflurane therapy administered for 10 days, alongside oxotropium bromide for the last 2 days. | Case study (level 4) | pH | 6.98 pre anaesthetic rising to 7.2 after 120 mins of isoflurane | Study states that effects of isoflurane, sevoflurane and halothane were all assessed during the case. No explanation fo method or duration of treatment No record of length of hospital stay No record of pulmonary function tests on discharge |
pCO2 | 105.5mmHg pre anaesthetic falling to 41.5mmHg after 120 mins of isoflurane | ||||
Duration of isoflurane therapy | 10 days (final 2 days with inhlaed oxotropium bromide) | ||||
Total length of intubation | 14 days | ||||
Mortality / Morbidity | Survived with normal blood results on discharge | ||||
F. Maltais, M. Sovilj et al. 1994 Canada | 3 patients (2 male, 1 female) with status asthmaticus refractory to conventional treatment. Intervention: Isoflurane therapy with dose tailored to each patient | Individual case control study (level 3b) | RMax (maximum respiratory resistance) | Maximum resistance decreased with isoflurane use | Only respiratory mechanics considered. Arterial blood gases for each patient were recorded prior to starting inhalational anesthetic but not recorded after stopping. No report of mortality or morbidity No statistics applied for significance of results |
RMin (minimum respiratory resistance) | Minimum resistance decreased with isoflurane use | ||||
Respiratory system compliance (Crs) | No significant change with isoflurane | ||||
Expiratory volume flow (to assess airway calibre) | Flow curve showed improvement with maximal isoflurane therapy | ||||
M. Bierman, M. Brown et al. 1986 USA | 34 year old female with refractory asthma. Mechanical ventilation and full medical therapy failed to improve symptoms and the patient was transferred to the operating department and administered 1% isoflurane for 30 minutes. | Case study (level 4) | Tidal volume | Increased with isoflurane | No record of total length of hospital stay No record of pulmonary function tests on discharge No statistics applied to look for significant improvement in data values |
pH | 7.23 on admission to 7.41 whilst anaesthetised | ||||
pO2 | On admission (10L oxygen) 108 torr improved to 23.2 torr with isoflurane | ||||
pC02 | 54 torr on admission improving to 40 torr with isoflurane | ||||
Intubation length | 3 days | ||||
Mortality | Survived |